Evidence map›Paper›PMID 28491035›Full record

ArticleFrontiers in pharmacology2017

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.

Alessandra Romano, Cesarina Giallongo, Piera La Cava, Nunziatina L Parrinello, Antonella Chiechi, Calogero Vetro, Daniele Tibullo, Francesco Di Raimondo, Lance A Liotta, Virginia Espina and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Alessandra RomanoDivisione di Ematologia, Azienda Ospedaliera Policlinico UniversitariaCatania, Italy.
Cesarina GiallongoDivisione di Ematologia, Azienda Ospedaliera Policlinico UniversitariaCatania, Italy.
Piera La CavaScuola Superiore di CataniaCatania, Italy.
Nunziatina L ParrinelloDivisione di Ematologia, Azienda Ospedaliera Policlinico UniversitariaCatania, Italy.
Antonella ChiechiCenter for Applied Proteomics and Molecular Medicine, George Mason UniversityManassas, VA, USA.
Calogero VetroDivisione di Ematologia, Azienda Ospedaliera Policlinico UniversitariaCatania, Italy.
Daniele TibulloDivisione di Ematologia, Azienda Ospedaliera Policlinico UniversitariaCatania, Italy.
Francesco Di RaimondoDivisione di Ematologia, Azienda Ospedaliera Policlinico UniversitariaCatania, Italy.
Lance A LiottaCenter for Applied Proteomics and Molecular Medicine, George Mason UniversityManassas, VA, USA.
Virginia EspinaCenter for Applied Proteomics and Molecular Medicine, George Mason UniversityManassas, VA, USA.
Giuseppe A PalumboDivisione di Ematologia, Azienda Ospedaliera Policlinico UniversitariaCatania, Italy.
Policlinico Universitario di Catania · ITGeorge Mason University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azacytidine (5-AZA) is the standard first-choice treatment for high-risk myelodysplasia (MDS) patients. However, the clinical outcome for those patients who interrupt treatment or whose disease failed to respond is very poor. In order to identify the cellular pathways that are modified by long-term exposure to 5-AZA, we evaluated key proteins associated with the autophagy pathway by reverse-phase microarray (RPPA). Comparing bone marrow mononucleated cells (BMMCs) obtained from 20 newly-diagnosed patients and after four 5-AZA cycles we found an increased autophagy signaling. We then evaluated

Indexed as

autophagyazacytidinemyelodysplastic syndrome

Identifiers

PMID28491035
PMCPMC5405131
OpenAlexW2607661124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.